



Cytheris names CFO and CMO as company boosts clinical development program in Europe and the US

Immune-modulation company strengthens top management team following promising Phase I/II results for its lead product, IL-7, in cancer and HIV infections

Paris. April 2, 2007—Cytheris, a product-oriented biopharmaceutical company focused on the research and development of new and critical agents for immune modulation, today announced the appointment of a chief financial and a chief medical officer. Bertrand Vannier becomes CFO and is in charge of the company's financial and business affairs in Europe and the US. Thérèse Croughs is named CMO and will oversee all clinical developments. In late 2006-early 2007, Cytheris announced promising preliminary results in Phase I/II clinical trials for its lead product, Interleukin-7. These showed an increase in T cells in patients with cancer and patients with HIV.

"The completion of a number of clinical trials on more than 60 patients makes it possible for Cytheris to announce a set of extremely good results in oncology and HIV infection, and we have taken the logical step of strengthening our management teams to ensure a smooth transition to the next stage of our development," said Michel Morre, CEO at Cytheris. "Bertrand Vannier's in-depth knowledge of the pharmaceutical industry, coupled with Thérèse Croughs' expertise in the medical fields which form the focus of Cytheris's activities, will allow us to continue our international development and tackle new strategic operations."

Vannier, 41, graduated from a French business school (Sciences-Po Paris) and holds a degree in finance from UC Berkeley. He has 15 years experience in auditing and corporate finance. He started his career as an auditor at Ernst & Young and joined Vivendi Group as a financial controller. Then, as a consultant, he conducted several IPOs on Euronext for high tech companies. From 2002, he was CFO of Unither Pharmaceuticals, a French contract manufacturer, where he had to work on LBO financings and acquisitions.

Croughs, 43, MD, is specialized in internal medicine. She received her MD from the School of Medicine at the Catholic University of Louvain, Brussels, Belgium where she served her residency. With more than 15 years experience in the pharmaceutical industry, she has acquired a high level of medical expertise in the fields of hematology, immunology, infectious diseases and cancer. Other relevant expertise includes clinical development in biotechnology (rFVIII, rFVIIa in particular) as well as regulatory affairs. She held various positions in Bayer, NovoNordisk and more recently at BioAlliance Pharma, where she was responsible for European medical affairs.

About Cytheris

Cytheris, Paris, is a product-oriented biopharmaceutical company focused on the research and development of new and critical agents for immune modulation. These drugs aim at reconstituting and enhancing the immune system of patients suffering from cancer, chronic viral or bacterial diseases (such as HIV and HCV) or lympho-depleting treatments (e.g. post-chemo,-BMT and -HCT).

The company's lead compound, recombinant Interleukin-7 (rIL-7) is a critical growth factor for immune T Cell recovery and enhancement. Clinical trials conducted on more than 60 patients in France and USA have already demonstrated the impressive ability of rIL-7 to expand and protect CD4⁺ and CD8⁺ T cells.

A second family of products is based on highly potent NKT/dendritic cell ligands, in-licensed from several New York universities. The product family strengthens innate and adaptive immunity connections and will provide new immuno-therapeutic adjuvants for cancer and chronic infectious diseases.

The company, founded in 1999, operates from Issy les Moulineaux, Paris and its US subsidiary in Rockville (MD). It has a network of strong and active collaborations with world-leading academic and clinical teams. Today Cytheris employs 22 experienced people in Europe and USA. Its investors include AXA Private Equity, Bioam Gestion, Credit Agricole Private Equity and CDC Innovation (Paris), T2C2 Bio2000 and CDPQ (Montreal), Forbion Capital Partners (Amsterdam). Website: www.cytheris.com

Media and analyst contact: Andrew Lloyd & Associates

Andrew Lloyd - Gilles Petitot
allo@ala.com - gilles@ala.com

Tel: 33 1 56 54 07 00
